newsfilter
← Latest News
GlobeNewswire·

Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research

  • Larimar Therapeutics (Nasdaq: LRMR) announced interim clinical data & new analyses on nomlabofusp for Friedreich's ataxia will be presented at ICAR 2026.
  • Three poster presentations covering long-term administration, plasma lipid profiles, & gene expression responses will occur on Thursday, November 12, 2026.
  • The poster session runs from 6:30 to 7:30 p.m. ET in Hall D at the Cobb Convention Center in Atlanta, Georgia.
  • Nomlabofusp is Larimar's lead compound being developed as a potential treatment for Friedreich's ataxia using an intracellular delivery platform.
Company
Larimar Therapeutics
Keywords
Nasdaq:LRMR, Larimar Therapeutics